MAPT and Alzheimer disease: Our initial aim was to determine if the NULISAseq CNS panel accurately detects amyloid and tau pathologies using tau phosphorylated at threonine 217 (pTau217), a Core 1 marker for AD diagnosis [1], and to compare pTau217 performance as part of a multiplex panel to the well-established Single molecule array (Simoa) singleplex assay.